Research programme: protein kinase inhibitors - Cancer Therapeutics

Drug Profile

Research programme: protein kinase inhibitors - Cancer Therapeutics

Alternative Names: CTx-0294886; CTX-0294945; CTx-294886; FAK inhibitors - Cancer Therapeutics; Focal adhesion kinase inhibitors - Cancer Therapeutics

Latest Information Update: 05 Apr 2012

Price : $50

At a glance

  • Originator Cytopia Limited
  • Developer Cancer Therapeutics CRC
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2012 Preclinical development is ongoing in Australia
  • 10 Mar 2010 Preclinical development is ongoing In Australia
  • 01 Feb 2010 Cytopia Limited has been acquired by YM BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top